Cartesian Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	26	110.78	85.08	16.6	6.68	0.9	0.21	8.08	6.01	3.04
Revenue Growth (YoY)	-76.53%	30.21%	412.60%	148.57%	639.42%	336.23%	-97.44%	34.47%	97.73%	-
Gross Profit	26	110.78	85.08	16.6	6.68	0.9	0.21	8.08	6.01	3.04
Selling, General & Admin	40.58	23.86	20.94	18.91	16.39	18.24	18.83	13.05	8.34	7.95
Research & Development	71.84	72.38	68.74	54.51	42.74	47.69	45.17	29.7	22.98	10.49
Operating Expenses	112.42	96.24	89.67	73.42	59.13	65.93	63.99	42.75	31.32	18.44
Operating Income	-86.42	14.54	-4.6	-56.82	-52.46	-65.02	-63.78	-34.67	-25.3	-15.4
Interest Expense / Income	2.83	3.03	2.84	1.56	1.52	1.49	1.21	1.25	0.95	0.55
Other Expense / Income	149.46	-23.26	2.28	10.5	1.38	-1.18	0.33	0.29	-1.08	-3.07
Pretax Income	-238.71	34.77	-9.72	-68.88	-55.35	-65.34	-65.32	-36.21	-25.17	-12.88
Income Tax	-19	-0.61	15.97	0	0	0	0	0	0	0
Net Income	-219.71	35.38	-25.69	-68.88	-55.35	-65.34	-65.32	-36.21	-25.17	-12.88
Preferred Dividends	0	0	0	0	0	0	0	4.57	7.34	3.49
Net Income Common	-219.71	35.38	-25.69	-68.88	-55.35	-65.34	-65.32	-40.78	-32.51	-16.37
Shares Outstanding (Basic)	5	5	4	3	2	1	1	0	0	0
Shares Outstanding (Diluted)	5	5	4	3	2	1	1	0	0	0
Shares Change	6.33%	27.59%	12.97%	122.19%	103.44%	9.62%	94.64%	387.99%	2.86%	-
EPS (Basic)	-49.80	7.20	-6.60	-20.40	-36.60	-87.60	-96.00	-116.70	-453.90	-235.20
EPS (Diluted)	-49.80	3.00	-6.60	-20.40	-36.60	-87.60	-96.00	-116.70	-453.90	-235.20
Free Cash Flow	-51.37	-32.83	-61.47	34.14	-51.36	-59.95	-52.76	-20.34	-23.63	-12.91
Free Cash Flow Per Share	-9.94	-6.80	-16.13	10.12	-33.83	-80.32	-77.49	-58.15	-329.60	-185.29
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-332.32%	13.12%	-5.40%	-342.36%	-785.61%	-7200.66%	-30813.53%	-428.92%	-420.96%	-506.55%
Profit Margin	-844.91%	31.94%	-30.19%	-414.99%	-828.97%	-7235.44%	-31556.04%	-504.47%	-540.83%	-538.55%
Free Cash Flow Margin	-197.53%	-29.64%	-72.25%	205.70%	-769.21%	-6638.54%	-25485.51%	-251.65%	-393.05%	-424.77%
Effective Tax Rate	-	-1.75%	-	-	-	-	-	-	-	-
EBITDA	-233.28	40.43	-4.51	-65.46	-51.8	-62.87	-63.37	-34.16	-23.18	-11.46
EBITDA Margin	-897.09%	36.49%	-5.30%	-394.40%	-775.86%	-6962.02%	-30611.11%	-422.55%	-385.66%	-377.11%
Depreciation & Amortization	2.6	2.62	2.37	1.86	2.03	0.98	0.75	0.8	1.04	0.86
EBIT	-235.88	37.8	-6.88	-67.32	-53.83	-63.84	-64.12	-34.96	-24.23	-12.33
EBIT Margin	-907.08%	34.12%	-8.08%	-405.62%	-806.22%	-7069.99%	-30973.43%	-432.48%	-403.03%	-405.53%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).